A Phase.b Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage

被引：0
|
作者：
Wang, Jiayu
Sun, Tao
Zhang, Qingyuan
Shi, Yanxia
Wang, Xu
Chen, Yiding
Ouyang, Quchang
Li, Kunyan
Bupathi, Manojkumar
Edenfield, W. Jeffery
Silber, Andrea L. M.
Zong, Hong
Hamilton, Erika
Juric, Dejan
Lathrop, Kate
Zhang, Yihong
Stazzone, Kathryn
Shi, Zhe
Wang, Yaolin
Zhang, Ling
Xu, Binghe
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS15-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS15-02
引用
收藏
页数：3
相关论文
共 50 条
  • [31] AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
    Aditya Bardia
    Sarat Chandarlapaty
    Hannah M. Linden
    Gary A. Ulaner
    Alice Gosselin
    Sylvaine Cartot-Cotton
    Patrick Cohen
    Séverine Doroumian
    Gautier Paux
    Marina Celanovic
    Vasiliki Pelekanou
    Jeffrey E. Ming
    Nils Ternès
    Monsif Bouaboula
    Joon Sang Lee
    Anne-Laure Bauchet
    Mario Campone
    Nature Communications, 13
  • [32] Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study.
    Musolino, Antonino
    Serra, Olga
    Pellegrino, Benedetta
    Tommasi, Chiara
    Zanoni, Daniele
    Cortesi, Laura
    Canino, Fabio
    Piacentini, Federico
    Sgargi, Paolo
    Michiara, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
    Bardia, Aditya
    Chandarlapaty, Sarat
    Linden, Hannah M.
    Ulaner, Gary A.
    Gosselin, Alice
    Cartot-Cotton, Sylvaine
    Cohen, Patrick
    Doroumian, Severine
    Paux, Gautier
    Celanovic, Marina
    Pelekanou, Vasiliki
    Ming, Jeffrey E.
    Ternes, Nils
    Bouaboula, Monsif
    Lee, Joon Sang
    Bauchet, Anne-Laure
    Campone, Mario
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [34] Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
    Lin, N. U.
    Borges, V. F.
    Patel, M. R.
    Okera, M.
    Meisel, J.
    Wesolowski, R.
    Pluard, T.
    Miller, K. D.
    McCarthy, N. J.
    Conlin, A. K.
    Mahtani, R.
    Sabanathan, D.
    McCann, K. E.
    Roesch, E.
    Mathauda-Sahota, G.
    Schroeder, J.
    Hamilton, E. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S338 - S338
  • [35] Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer-a problem still to be solved
    Schmidt, M.
    Untch, M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 754 - 754
  • [36] A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer
    Borges, Virginia F.
    Chan, Arlene
    Lin, Nancy U.
    Tonda, Margaret Eleanor
    Shilkrut, Mark
    Alemany, Carlos A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2-BC): Results from a phase I study dose-expansion part
    Yonemori, K.
    Miyoshi, Y.
    Yasojima, H.
    Watanabe, J.
    Takano, T.
    Shimomura, A.
    Tokunaga, E.
    Mukohara, T.
    Naoi, Y.
    Okumura, S.
    Suzuki, T.
    Otake, Y.
    Matsuoka, D.
    Takase, T.
    Semba, T.
    Ishiguro, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S352 - S353
  • [38] Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer
    Seki, Hirohito
    Sakurai, Takashi
    Sakurada, Akihisa
    Kinoshita, Tetsuhiko
    Shimizu, Ken
    ANTICANCER RESEARCH, 2022, 42 (02) : 1099 - 1106
  • [39] Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)
    Hamilton, E.
    Meisel, J.
    Alemany, C.
    Virginia, B.
    Lin, N.
    Wesolowski, R.
    Mathauda-Sahota, G.
    Makower, D.
    Lawrence, J.
    Faltaos, D.
    Mitri, Z.
    Sabanathan, D.
    Clark, D.
    Pluard, T.
    Hui, R.
    McCarthy, N.
    Patel, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S36 - S36
  • [40] Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study
    Lashen, Ayat G.
    Toss, Michael
    Miligy, Islam
    Rewcastle, Emma
    Kiraz, Umay
    Janssen, Emiel A. M.
    Green, Andrew R.
    Quinn, Cecily
    Ellis, Ian
    Rakha, Emad A.
    HISTOPATHOLOGY, 2024, 85 (03) : 468 - 477
12345